Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved Watson Pharmaceuticals' Androderm (testosterone transdermal system) 2 mg and 4 mg formulation, which is likely to be launched in November 2011.
Subscribe to our email newsletter
Androderm,a once daily skin patch, called a transdermal delivery system, is a testosterone replacement therapy in males with a deficiency or absence of endogenous testosterone. It delivers consistent, controlled concentrations of testosterone through the skin.
The new testosterone patch which comes in smaller size and lower-dose provides 20% reduction in the active ingredient from the original strength in a smaller patch size.
The approval occured following a trial that demonstrated 97% of the subjects achieved testosterone concentrations within the normal range after 28 days of daily therapy.